fluoxetine has been researched along with Menopause in 17 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
Excerpt | Relevance | Reference |
---|---|---|
"This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women." | 9.51 | Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial. ( Álvarez-Pérez, MA; Bajonero-Domínguez, A; Cruz-Luna, M; Garmendia-Gallardo, C; González-Quiroz, JL; Hernández-Castañón, MY; Hernández-Hernández, VY; Loranca-Moreno, P; Ocampo-Godínez, JM; Rios-Espinosa, A; Sánchez-Tinoco, PM; Vergara Lope-Núñez, JA, 2022) |
"This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women." | 5.51 | Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial. ( Álvarez-Pérez, MA; Bajonero-Domínguez, A; Cruz-Luna, M; Garmendia-Gallardo, C; González-Quiroz, JL; Hernández-Castañón, MY; Hernández-Hernández, VY; Loranca-Moreno, P; Ocampo-Godínez, JM; Rios-Espinosa, A; Sánchez-Tinoco, PM; Vergara Lope-Núñez, JA, 2022) |
"Results from these trials indicate that paroxetine, citalopram, escitalopram, venlafaxine, and desvenlafaxine are effective in reducing the frequency and severity of hot flashes." | 4.91 | The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. ( Handley, AP; Williams, M, 2015) |
" FL did not affect thermic response to oral glucose neither after acute nor chronic administration (p=NS for all groups studied)." | 2.69 | Metabolic effects of fluoxetine in obese menopausal women. ( Bertolini, M; Bondi, M; Del Rio, G; Menozzi, R; Venneri, MG, 2000) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (17.65) | 18.2507 |
2000's | 8 (47.06) | 29.6817 |
2010's | 5 (29.41) | 24.3611 |
2020's | 1 (5.88) | 2.80 |
Authors | Studies |
---|---|
Rios-Espinosa, A | 1 |
Cruz-Luna, M | 1 |
Garmendia-Gallardo, C | 1 |
Hernández-Castañón, MY | 1 |
Hernández-Hernández, VY | 1 |
Sánchez-Tinoco, PM | 1 |
Bajonero-Domínguez, A | 1 |
Vergara Lope-Núñez, JA | 1 |
Álvarez-Pérez, MA | 1 |
González-Quiroz, JL | 1 |
Loranca-Moreno, P | 1 |
Ocampo-Godínez, JM | 1 |
Macías-Cortés, ED | 1 |
Llanes-González, L | 1 |
Aguilar-Faisal, L | 1 |
Asbun-Bojalil, J | 1 |
Coelho, GA | 1 |
Rodrigues, E | 1 |
Andersen, ML | 1 |
Tufik, S | 1 |
Hachul, H | 1 |
Kornstein, SG | 1 |
Pedersen, RD | 1 |
Holland, PJ | 1 |
Nemeroff, CB | 1 |
Rothschild, AJ | 1 |
Thase, ME | 1 |
Trivedi, MH | 1 |
Ninan, PT | 1 |
Keller, MB | 1 |
Handley, AP | 1 |
Williams, M | 1 |
Zhu, X | 1 |
Liew, Y | 1 |
Liu, ZL | 1 |
Liu, P | 1 |
He, FF | 2 |
Bai, WP | 1 |
Yu, Q | 2 |
Shi, W | 1 |
Wu, YY | 2 |
He, DJ | 1 |
Xiao, JH | 1 |
Zheng, Y | 1 |
Liao, QP | 1 |
Yin, CX | 1 |
Hui, Y | 1 |
Yu, J | 1 |
Wei, J | 1 |
Gaszner, P | 1 |
Albertazzi, P | 1 |
Epperson, CN | 1 |
Amin, Z | 1 |
Naftolin, F | 1 |
Cappiello, A | 1 |
Czarkowski, KA | 1 |
Stiklus, S | 1 |
Anderson, GM | 1 |
Krystal, JH | 1 |
Alexander, IM | 1 |
Moore, A | 1 |
Amsterdam, JD | 1 |
Garcia-España, F | 1 |
Goodman, D | 1 |
Hooper, M | 1 |
Hornig-Rohan, M | 1 |
Bondi, M | 1 |
Menozzi, R | 1 |
Bertolini, M | 1 |
Venneri, MG | 1 |
Del Rio, G | 1 |
Parry, BL | 1 |
Newton, RP | 1 |
Urban, RJ | 1 |
Veldhuis, JD | 1 |
Forrest, DV | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445] | 91 participants (Actual) | Interventional | 2021-01-20 | Completed | |||
Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol[NCT01635218] | Phase 2 | 133 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term[NCT00046020] | Phase 4 | 1,096 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
Interaction of Estrogen and Serotonin in Modulating Brain Activation in Menopause[NCT01208324] | 47 participants (Actual) | Interventional | 2010-03-04 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
17-item Hamilton Rating Scale for Depression (HRSD) is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in HRSD was assessed at baseline and after six weeks of treatment. For this study the change was calculated as the later time point (total score in 17- HRSD at 6 weeks) minus the earlier time point (total score at baseline). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks
Intervention | Units in Hamilton Scale (Mean) |
---|---|
Individualized Homeopathic Treatment | 9.9 |
Fluoxetine | 11.7 |
Placebo | 15 |
Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory that assess severity of depression. A total score range was assessed at baseline and after six weeks of treatment. A score 0 (without depression) up to 63 (most severe depression). For this study the change was calculated as the later time point (total score in BDI at 6 weeks) minus the earlier time point (total score in BDI at baseline). A score 0 - 8 is considered normal, 9 - 18 (mild to moderate depression), 19 - 28 (moderate to severe depression), > 29 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks
Intervention | Units in Beck Depression Inventory (Mean) |
---|---|
Individualized Homeopathic Treatment | 12 |
Fluoxetine | 14.2 |
Placebo | 15.5 |
Greene Climacteric Scale (GS) is intended to be a standard measure of core climacteric symptoms. For this study a total range was assessed at baseline and after six weeks of treatment. A total score 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). The change was calculated as the later time point (total score in GS at 6 weeks) minus the earlier time point (total score at baseline).The scale measures four separate sub-scales (anxiety, depression, somatic symptoms and sexual function). The score of the four sub-scales was summed. A total score of 0 -10 is considered without symptoms, 11 - 29 (mild symptoms), 30 - 49 (moderate symptoms) and > 50 (severe symptoms). (NCT01635218)
Timeframe: Baseline and 6 weeks
Intervention | Units in Green Scale (Mean) |
---|---|
Individualized Homeopathic Treatment | 18.1 |
Fluoxetine | 23.1 |
Placebo | 26.8 |
17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Remission rate definition: 17-item Hamilton Rating Scale for Depression score < 7 points after 6 weeks of treatment. (NCT01635218)
Timeframe: 6 weeks
Intervention | participants with a score of < 7 in HS (Number) |
---|---|
Individualized Homeopathic Treatment | 7 |
Fluoxetine | 7 |
Placebo | 2 |
17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Responder rate definition: a decrease of 50% or more from baseline score using 17-item Hamilton Rating Scale for Depression after six weeks treatment. (NCT01635218)
Timeframe: 6 weeks
Intervention | participants with a decrease >50% in HS (Number) |
---|---|
Individualized Homeopathic Treatment | 24 |
Fluoxetine | 19 |
Placebo | 5 |
To replicate and extend our previous behavioral findings of an interaction between estrogen therapy (ET) and tryptophan depletion on verbal memory in a group of early menopausal women randomized to receive ET. Blood-oxygen-level dependent or BOLD signal is the outcome of BOLD imaging, which is a technique used in functional MRI. BOLD signal reflects changes in regional cerebral blood flow which delineate regional activity. A positive BOLD signal marks an increase in regional blood flow, while a negative BOLD signal marks a decrease in regional blood flow. A positive percent change means that between scans the BOLD signal i.e. blood flow in that region has increased, a negative percent change means that the BOLD signal has decreased between scans. (NCT01208324)
Timeframe: 8 weeks
Intervention | percentage of BOLD signal changes (Mean) |
---|---|
High Ace | -.43 |
Low Ace | .20 |
5 reviews available for fluoxetine and Menopause
Article | Year |
---|---|
The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
Topics: Adult; Aged; Citalopram; Desvenlafaxine Succinate; Female; Fluoxetine; Hot Flashes; Humans; Menopaus | 2015 |
Chinese herbal medicine for menopausal symptoms.
Topics: Drugs, Chinese Herbal; Estazolam; Female; Fluoxetine; Hormone Replacement Therapy; Hot Flashes; Huma | 2016 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapin | 2006 |
Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Topics: Adrenergic alpha-Agonists; Algorithms; Amines; Citalopram; Clonidine; Complementary Therapies; Cyclo | 2007 |
Chronobiological basis of female-specific mood disorders.
Topics: Antidepressive Agents, Second-Generation; Chronobiology Phenomena; Cross-Over Studies; Depression, P | 2001 |
9 trials available for fluoxetine and Menopause
Article | Year |
---|---|
Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.
Topics: Citalopram; Female; Fluoxetine; Humans; Menopause; Postmenopause; Prospective Studies; Syndrome | 2022 |
Is metabolic dysregulation associated with antidepressant response in depressed women in climacteric treated with individualized homeopathic medicines or fluoxetine? The HOMDEP-MENOP Study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Fem | 2017 |
Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; | 2014 |
Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine.
Topics: Adult; Depressive Disorder; Estrogen Replacement Therapy; Female; Fluoxetine; Humans; Menopause; Mid | 2004 |
[Comparison of the effect of fluoxetine combined with hormone replacement therapy (HRT) and single HRT in treating menopausal depression].
Topics: Adult; Climacteric; Depressive Disorder; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); | 2004 |
About the menopausal depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The | 2005 |
Metabolic effects of fluoxetine in obese menopausal women.
Topics: Antidepressive Agents, Second-Generation; Blood Glucose; Body Temperature Regulation; Double-Blind M | 2000 |
Chronobiological basis of female-specific mood disorders.
Topics: Antidepressive Agents, Second-Generation; Chronobiology Phenomena; Cross-Over Studies; Depression, P | 2001 |
A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women.
Topics: Circadian Rhythm; Female; Fluoxetine; Humans; Menopause; Middle Aged; Models, Biological; Osmolar Co | 1991 |
4 other studies available for fluoxetine and Menopause
Article | Year |
---|---|
Psychotherapy improved the sleep quality in a patient who was a victim of child sexual abuse: a case report.
Topics: Antidepressive Agents, Second-Generation; Child; Child Abuse, Sexual; Crime Victims; Female; Fluoxet | 2013 |
The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings.
Topics: Adult; Affect; Cognition; Depressive Disorder, Major; Drug Therapy, Combination; Estradiol; Female; | 2007 |
Breast enlargement during chronic antidepressant therapy.
Topics: Breast; Breast Diseases; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Hyperplasia | 1997 |
Reappearance of menses in a patient taking fluoxetine.
Topics: Female; Fluoxetine; Humans; Menopause; Menstruation; Middle Aged | 1990 |